Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open Label, Randomized, Comparative Study Of CP-675,206 And Either Dacarbazine Or Temozolomide In Patients With Advanced Melanoma

NCT00257205 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00257205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00257205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open Label, Randomized, Comparative Study Of CP-675,206 And Either Dacarbazine Or Temozolomide In Patients With Advanced Melanoma
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2006
Completion date
August 31, 2010
Enrollment
655 (actual)
Sites
143

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma